We are live on
!
Find out more
Lyell Immunopharma
LYEL
LYEL
119 hedge funds and large institutions have $194M invested in Lyell Immunopharma in 2024 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 45 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
21% more call options, than puts
Call options by funds: $17K | Put options by funds: $14K
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more ownership
Funds ownership: 2.61% → 2.62% (+0%)
6% less funds holding
Funds holding: 127 → 119 (-8)
27% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 45
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
35% less capital invested
Capital invested by funds: $297M → $194M (-$103M)
Holders
119
Holders Change
-8
Holders Change %
-6.3%
% of All Funds
1.72%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
16
Increased
33
Reduced
45
Closed
22
Calls
$17K
Puts
$14K
Net Calls
+$3K
Net Calls Change
+$4K
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$14.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.72M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.78M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.25M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$875K |
Top Sellers
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.01M |
| 2 |
Millennium Management
New York
|
-$2.92M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$2.29M |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$1.94M |
| 5 |
JP Morgan Chase
New York
|
-$1.33M |
